EGFR and neoplasm: Cetuximab is a common targeted therapeutic agents, which serves as epidermal growth factor receptor (EGFR) inhibitor and suppresses the progression of tumor growth, invasion and metastasis.[1] Since 2004, a widespread application of cetuximab has obviously improved the survival of the patients with epithelial cancer.